Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS (REGN)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 06/20 07:10:01 pm
331.375 USD   +1.32%
12:24pREGENERON PHARM : Decibel raises $55M in series C, names Scangos cha..
AQ
08:02aLatecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19NASDAQ 100 MOVE : Jd, regn
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Regeneron Pharmaceuticals : Sanofi beats profit forecasts, upbeat on prospects for eczema drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2017 | 10:30am CEST
A logo is seen in front of the entrance at the headquarters of French drugmaker Sanofi in Paris

PARIS (Reuters) - French drugmaker Sanofi's (>> Sanofi) profit beat forecasts in the first quarter and confirmed its earnings outlook for the year, lifting its shares on Friday.

PARIS (Reuters) - French drugmaker Sanofi's (>> Sanofi) profit beat forecasts in the first quarter and confirmed its earnings outlook for the year, lifting its shares on Friday.

The results were buoyed by Sanofi's speciality care division Genzyme, as well as vaccines and consumer products it has acquired from Germany's Boehringer Ingelheim.

Earlier this year, Sanofi had warned investors it expected 2017 earnings per share to be stable or slightly lower after its fourth quarter results were affected by an increase in taxes and one-off charges.

The company had also said in 2015 it was not targeting any 'meaningful' profit growth for two years, citing difficulties in its embattled diabetes division.

"Although it has now some margin to deliver actual numbers above guidance, Sanofi also has reasons to wait a bit more before raising it. Diabetes is still a very uncertain market segment to work in," Bryan Garnier analysts said in a note.

However, Sanofi, whose shares were up more than 2 percent at 0805 GMT, said it was confident Dupixent, a drug for moderate-to-severe atopic dermatitis that was approved in the United States at the end of last month, would sell well.

Analysts forecast annual Dupixent sales of more than $4 billion (£3.10 billion) by 2022, according to Thomson Reuters data. Developed with Regeneron (>> Regeneron Pharmaceuticals Inc), the drug is seen as the most important growth driver for the two companies, who have said Dupixent will have a list price of $37,000 a year.

Sanofi Chief Executive Olivier Brandicourt told journalists that he was "very encouraged with the early coverage" of Dupixent, adding that "the launch is delivering so far exactly on our expectations".

While the price of Dupixent before discounts and rebates to insurers is far more expensive than topical medicines and steroids used to treat eczema, it is less expensive than other injectable antibody drugs for serious skin conditions, such as psoriasis, that list for about $50,000 a year.

CONSUMER HEALTHCARE SHINES

Sanofi said on Friday first-quarter business net income rose 1 percent at constant exchange rates to 1.8 billion euros (£1.51 billion). Total sales rose 8.6 percent to 8.65 billion.

Analysts polled by Reuters in partnership with Inquiry Financial had on average been expecting business net profit of 1.6 billion euros and net sales of 8.38 billion.

Genzyme's sales were up 15.5 percent while revenue at the vaccines divisions rose 22.2 percent. Consumer healthcare products sales were up 42.7 percent.

Hurt by continued U.S. pricing pressure, diabetes and cardiovascular sales however suffered another downturn with revenue falling 7.7 percent.

(Additional reporting by Matthieu Protard; Editing by Leigh Thomas and Alexander Smith)

By Matthias Blamont

Stocks treated in this article : Sanofi, Regeneron Pharmaceuticals Inc
Stocks mentioned in the article
ChangeLast1st jan.
SANOFI 0.95% 68.31 Real-time Quote.-4.41%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
02:02pTODAY'S RESEARCH REPORTS ON TRENDING : Regeneron Pharmaceuticals and Intrexon
AC
12:24pREGENERON PHARMACEUTICALS : Decibel raises $55M in series C, names Scangos chair..
AQ
08:02aLatecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19NASDAQ 100 MOVERS : Jd, regn
AQ
06/14REGENERON PHARMACEUTICALS : Researchers from Regeneron Pharmaceuticals Provide D..
AQ
06/14REGENERON PHARMACEUTICALS : and Zoetis Announce Collaboration to Research Antibo..
AQ
06/13REGENERON PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Hold..
AQ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/11REGENERON : Back Above $300
AQ
06/11REGENERON PHARMACEUTICALS : Report
CO
More news
News from SeekingAlpha
06/15Brief Mid-Year Update On 2018 Global Asset Allocation 
06/12Regeneron Pharmaceuticals (REGN) Presents At Goldman Sachs 39th Annual Global.. 
06/11Regeneron Pharmaceuticals (REGN) Investor Presentation - Slideshow 
06/11YOUR DAILY PHARMA SCOOP : Scynexis Moves Up, Proteostasis Disappoints Investors,.. 
06/08EC OKs AstraZeneca's Tagrisso for first-line lung cancer 
Financials ($)
Sales 2018 6 321 M
EBIT 2018 2 525 M
Net income 2018 1 807 M
Finance 2018 3 194 M
Yield 2018 -
P/E ratio 2018 21,20
P/E ratio 2019 19,03
EV / Sales 2018 4,78x
EV / Sales 2019 3,99x
Capitalization 33 439 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 25
Average target price 374 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-16.13%33 439
GILEAD SCIENCES-1.97%89 796
VERTEX PHARMACEUTICALS3.44%38 655
NEUROCRINE BIOSCIENCES, INC.31.87%9 196
GENMAB-6.69%9 076
BEIGENE LTD (ADR)68.95%8 984